RenovoRx (RNXT) announced that the Northwell Health Cancer Institute, NHCI, in New Hyde Park, NY is enrolling patients with locally advanced pancreatic cancer, LAPC, in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. NHCI joins clinical sites throughout the United States participating in the study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT: